These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 22496780

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
    Kivisäkk P, Francois K, Mbianda J, Gandhi R, Weiner HL, Khoury SJ.
    PLoS One; 2014; 9(7):e103716. PubMed ID: 25075741
    [Abstract] [Full Text] [Related]

  • 3. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
    Harrer A, Wipfler P, Einhaeupl M, Pilz G, Oppermann K, Hitzl W, Afazel S, Haschke-Becher E, Strasser P, Trinka E, Kraus J.
    J Neuroimmunol; 2011 May; 234(1-2):148-54. PubMed ID: 21450349
    [Abstract] [Full Text] [Related]

  • 6. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
    Gandoglia I, Ivaldi F, Carrega P, Armentani E, Ferlazzo G, Mancardi G, Kerlero de Rosbo N, Uccelli A, Laroni A.
    Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D'Agosto G, Cordiali-Fei P.
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
    Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E.
    Eur Neurol; 2010 Jun; 63(5):311-7. PubMed ID: 20453514
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
    Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, Du Pasquier RA.
    Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis.
    Frisch ES, Häusler D, Weber MS.
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37072216
    [Abstract] [Full Text] [Related]

  • 12. Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.
    Waschbisch A, Sammet L, Schröder S, Lee DH, Barrantes-Freer A, Stadelmann C, Linker RA.
    Clin Exp Immunol; 2014 Aug; 177(2):404-11. PubMed ID: 24730443
    [Abstract] [Full Text] [Related]

  • 13. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 14. [Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis].
    Kümpfel T, Heydari N, Hohlfeld R.
    Nervenarzt; 2002 Jun; 73(6):552-5. PubMed ID: 12243004
    [Abstract] [Full Text] [Related]

  • 15. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.
    Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H.
    J Exp Med; 2014 Aug 25; 211(9):1833-46. PubMed ID: 25135296
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab treatment reduces endothelial activity in MS patients.
    Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F.
    J Neuroimmunol; 2010 Oct 08; 227(1-2):190-4. PubMed ID: 20739072
    [Abstract] [Full Text] [Related]

  • 20. The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
    Møller M, Søndergaard HB, Koch-Henriksen N, Sorensen PS, Sellebjerg F, Oturai AB.
    Acta Neurol Scand; 2014 Jan 08; 129(1):27-31. PubMed ID: 23668375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.